# Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants

> **NCT03876301** · — · COMPLETED · sponsor: **Spark Therapeutics, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Blood Coagulation Disorder
- Blood Coagulation Disorders, Inherited
- Coagulation Protein Disorders
- Hemophilia A
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Hematologic Diseases
- Hemorrhagic Disorders
- Factor VIII Deficiency

## Interventions

- **DRUG:** Standard of Care FVIII Replacement therapy

## Key facts

- **NCT ID:** NCT03876301
- **Lead sponsor:** Spark Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-21
- **Primary completion:** 2023-05-02
- **Final completion:** 2023-05-02
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2023-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03876301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03876301, "Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03876301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*